Amisulpride IV Treatment

Phase 3Small molecule

Amisulpride IV Treatment is one of 42 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nausea and VomitingRecruiting

Nausea and VomitingPhase 3

Recruiting

Competition

Competitive Landscape

78 competitors in Nausea and Vomiting

#DrugCompanyPhaseTrials

Zyprexa

MMODAG GmbH

Approved

16 2

Reglan

IIstituto Clinico Humanitas

Approved

13 3

Olinvyk

TTrevena Inc.

Approved

1 4

Thalomid

Bristol-Myers Squibb

Phase 3

2 5

Gemzar

Johnson & Johnson

Phase 3

1 6

Megace

Bristol-Myers Squibb

Phase 3

1 7

Abraxane

Bristol-Myers Squibb

Phase 3

1 8

Nereus

VVanda Pharmaceuticals

Phase 3

2 9

Qbrexza

PPeking Union Medical College Hospital

Approved

1 10

HSK21542

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nausea and vomiting1 trial

A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population

Recruiting·—·Phase 3·NCT06585540·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Amisulpride IV Treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Amisulpride IV Treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Amisulpride IV Treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Benaroya Research Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBenaroya Research Institute

Amisulpride IV Treatment

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nausea and vomiting1 trial

References

Drug Info

Quick Facts

Related News